Mirum Pharmaceuticals (MIRM) Shares Outstanding (Diluted Average) (2021 - 2026)
Mirum Pharmaceuticals (MIRM) recorded quarterly Shares Outstanding (Diluted Average) of $58.9 million in Q1 2026, up 17.24% quarter-over-quarter from $50.2 million in Q4 2025, and up 20.38% on a YoY basis from $48.9 million in Q1 2025.
Mirum Pharmaceuticals (MIRM) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $58.9 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 20.38% year-over-year to $58.9 million; the TTM figure through Mar 2026 stood at $58.9 million (up 20.38% YoY), while the FY2025 annual figure was $50.2 million, up 5.63% from the prior year.
- Shares Outstanding (Diluted Average) was $58.9 million for Q1 2026 at Mirum Pharmaceuticals, up from $50.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $58.9 million in Q1 2026 to a low of $31.3 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $43.5 million across 5 years, with a median of $46.9 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) grew 24.56% in 2024, then rose 4.18% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $34.0 million in 2022, then grew by 20.31% to $40.9 million in 2023, then climbed by 16.23% to $47.5 million in 2024, then climbed by 5.63% to $50.2 million in 2025, then climbed by 17.24% to $58.9 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $58.9 million (Q1 2026), $50.2 million (Q4 2025), and $57.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Mirum Pharmaceuticals | 6.29 Bn | 5.90 Bn | 131.08 Mn | 58.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.85 Mn |
| Dec 31, 2025 | 50.20 Mn |
| Sep 30, 2025 | 56.99 Mn |
| Jun 30, 2025 | 49.31 Mn |
| Mar 31, 2025 | 48.89 Mn |
| Dec 31, 2024 | 47.52 Mn |
| Sep 30, 2024 | 47.78 Mn |
| Jun 30, 2024 | 47.08 Mn |
| Mar 31, 2024 | 46.93 Mn |
| Dec 31, 2023 | 40.89 Mn |
| Sep 30, 2023 | 38.97 Mn |
| Jun 30, 2023 | 37.89 Mn |
| Mar 31, 2023 | 37.68 Mn |
| Dec 31, 2022 | 33.98 Mn |
| Sep 30, 2022 | 32.83 Mn |
| Jun 30, 2022 | 31.74 Mn |
| Mar 31, 2022 | 31.30 Mn |
| Sep 30, 2021 | 30.37 Mn |
| Jun 30, 2021 | 30.27 Mn |